Peptide hormones and lung cancer

Panminerva Medica

Volumn 48, Issue 1, 2006, Pages 19-26

  Moody, T W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adremedullin; Gastrin releasing peptide; Lung neoplasms; Neurotensin

Indexed keywords

ADRENOMEDULLIN; GASTRIN RELEASING PEPTIDE; NEUROTENSIN; PEPTIDE; PEPTIDE HORMONE;

AMINO ACID SEQUENCE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MOLECULAR GENETICS; REVIEW; SMALL CELL CARCINOMA;

ADRENOMEDULLIN; AMINO ACID SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; GASTRIN-RELEASING PEPTIDE; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; NEUROTENSIN; PEPTIDE HORMONES; PEPTIDES;

EID: 33745031603     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Sekido Y, Fong KM, Minna JD. Molecular biology of lung cancer. In: DeVita VT, Hellman S, Rosenberg SA editors. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins; 2001. p.917-25.
2. Ginsberg RJ, Vokes EE, Rosenzweig K. Non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA editors. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia: Lippincott, Williams and Wilkins, 2001.p.925-1018.
3. Lynch TJ, Bell DW, Sordella R, Gurubbagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
4. Paez, JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
5. Pfeifer GP, Denissenko MF, Olivier M, Tretyskova, N, Hecht SS, Hainut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002;21:7435-51.
6. Carney DN, Gazdar AF, Bepler G, Guccion JG, Marangos PJ, Moody TW et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-23.
7. Moody TW, Pert CB, Gazdar AF, Carney DN, Minna, JD. High levels of intracellular bombesin characterize human small-cell lung carcinoma. Science 1981;214:1246-8.
8. Moody TW, Carney DN, Cuttitta F, Quattrochi K, Minna JD. High affinity receptors for bombesin/GRP-like peptides on human small cell lung cancer. Life Sci 1985;37:105-13.
9. Trepel, JB, Moyer JD, Heikkila R, Sausville EA. Modulation of bombesin-induced phosphatidyl inositol hydrolysis in a small cell lung cancer cell line. Biochem J 1988;255:403-10.
10. Moody TW, Murphy A, Mahmoud S, Fiskum G. Bombesin-like peptides elevate cytosolic calcium in small cell lung cancer cells. Biochem Biophys Res Commun 1987;147:189-95.
11. Koh SWM, Leyton J, Moody TW. Bombesin activates MAP kinase in non-small cell lung cancer cells. Peptides 1999;20:121-6.
12. Draoui M, Chung P, Park M, Birrer M, Jakowlew S, Moody TW. Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer cells. Peptides 1995;16:289-92.
13. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer cells. Nature 1985;316:823-6.
14. Moody TW, Zia F, Venugopal R, Patierno S, LeBan J, McDermod J. BW2258: A GRP receptor antagonist which inhibits small cell lung cancer growth. Life Sci 1995;56:523-9.
15. Moody TW, Leyton J, Garcia L, Jensen RT. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur J Pharmacol 2003;474:21-9.
16. Miller MJ, Martínez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T et al. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996;271:23345-51.
17. Moody TW, Carney DN, Korman LY, Gazdar AF, Minna JD. Neurotensin is produced by and secreted from classic small cell lung cancer cells. Life Sci 1985;36:1727-32.
18. Staley J, Fiskum G, Davis TP, Moody TW. Neurotensin elevates cytosolic calcium in SCLC cells. Peptides 1989;10:1217-21.
19. Leyton J, Moody TW, Garcia-Marin L, Jensen RT. Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in non-small cell lung cancer cells. Eur J Pharm 2002;442:179-86.
20. Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 2001;22:109-115.
21. Moody TW, Miller MJ, Martinez A, Unsworth E, Cuttitta F. Adrenomedullin binds with high affinity, elevates cAMP and stimulates c-fos expression in C6 glioma cells. Peptides 1997;18:1111-5.
22. Martínez A, Julían M, Bregonzio C, Naotari L, Moody TW, Cuttitta F. Identification of vasoactive nonpeptide positive and negative modulators of adrenomedullin using a neutralizing antibody-based screening strategy. Endocrinology 2004;145:3858-65.
23. Falconieri Erspamer G, Severini C, Erspamer V, Melchiorri P, Delle Fave G, Nakajima T. Parallel bioassay of 27 bombesin-like peptides on 9 smooth muscle preparations. Structure-activity relationships and bombesin receptor subtypes. Regul Pept 1988;21:1-11.
24. McDonald, TJ, Jornvall J, Nilsson G, Vagne M, Ghatei M, Bloom SR et al. Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem Biophys Res Commun 1979;90:227-33.
25. Spindel ER, Zilberberg MD, Habener JF, Chin WW. Two prohormones for gastrin-releasing peptide are endoced by two mRNAs differing by 19 nucleotides. Proc Natl Acad Sci USA 1986;83:19-23.
26. Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake K et al. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001;32:61-9.
27. Giaccone G, Battey J, Gazdar AF, Oie H, Draoui M, Moody TW. Neuromedin B is present in lung cancer cell lines. Cancer Res 1992;52:27352s-62.
28. Said SI, Mutt V. Polypeptide with broad biological activity: Isolation from the small intestine. Science 1970;69:1217-8.
29. Korman LY, Carney DN, Citron ML, Moody TW. Secretin/VIP stimulated secretion of bombesin-like peptides from human small cell lung cancer. Cancer Res 1986;46:1214-8.
30. Lee M, Jensen RT, Bepler G, Korman LY, Moody TW. Vasoactive intestinal polypeptide binds with high affinity to non-small cell lung cancer cells and elevates cAMP levels. Peptides 1990;11:1205-10.
31. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q el al. 1231-labeled vasoactive intestinal peptide (VIP) for the localization of intestinal adenocarinomas and endocrine tumor. N Engl J Med 1994;331:1116-21.
32. Radener M, Kurtanan A, Leimer M, Angelberger P, Niederle B. Vierhapper H et al. Value of peptide receptor scintigraphy using 123I-vasoactive intestinal peptide and 111 In-DPTA-D-Phel -octreotide in 194 carcinoid patients: Vienna University experience, 1993-1998. J Clin Oncol 2000;18:1331-6.
33. Pallela VR, Thakur ML, Chakder S, Rattan S. 99m Tc-labeled vasoactive intestinal peptide receptor agonist: functional studies. J Nucl Med 1999;40:352-60.
34. Moody TW, Leyton J, Unsworth E, John C, Lang L, Eckelman W. (Arg15, Arg21)VIP: A VIP agonist for localizing breast cancer tumors. Peptides 1998;19:585-92.
35. Taylor, JE, Moreau JP, Baptiste L, Moody TW. Octapeptide analogues of somatostatin inhibit the clonal growth and VIP-stimulated cAMP formation in human small cell lung cancer cells. Peptides 1991;12:839-43.
36. Taylor JE, Theveniau MA, Bashirzadeh R, Resine T, Eden PA. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 1994;15:1229-36.
37. Gibril F, Reynolds JC, Lubensky IA, Roy PK, Peghini PL, Doppman JL et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 2000;41:1646-56.
38. John M, Meyerhof W, Richter D, Waser B, Schaer J, Scherubl H et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996;38:33-9.
39. Behr TM, Gotthardt M, Bardth A, Behe MQ. Imaging tumors with peptide-based radioligands. J Nucl Med 2001;45:189-200.
40. Thomason JWW, Martin RS, Fincher ME. Somatostatin receptor scintigraphy: the definitive technique for characterizing VIP-secreting tumors. Clin Nucl Med 2000;25:661-4.
41. Reubi JC, Kvols L, Krenning E, Lamberts SWJ. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990;39:78-81.
42. Bohuslavizki KH, Brenner W, Gunther M, Eberhardt JU, Jahn N, Tinnemeyer S et al. Somatostatin scintigraphy in the staging of small cell lung cancer. Nucl Med Commun 1996;17:191-6.
43. Kelly MJ, Linnoila RI, Avis IL, Georgiadis MS, Cuttitta F, Mulshine JL. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest 1997;112:256-61.
44. Moody TW, Chan D, Fahrenkrug J, Jensen RT. Neuropeptides as autocrine growth factors in cancer cells. Curr Pharm Des 2003;9:495-509.
45. Reubi JC, Wenger S, Schumuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radoligand (125)I-[D-TYR(6), beta-ALA(11),PHE(13), NLE(14)] bombesin(6-14). Clin Cancer Res 2002;8:1139-46.
46. Zhou J, Chen J, Mokotoff M, Ball ED. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs 2004;15:921-7.
47. Mahmoud S, Staley J, Taylor J, Bogden A, Moreau JP, Coy D, Avis I et al. (Psi 13,14)Bombesin analogues inhibit the growth of small cell lung cancer in vitro and in vivo. Cancer Res 1991;51:1798-802.
48. Mantey SA, Weber HC, Sainz E, Akeson M, Ryan RR, Pradhan T et al. Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates it has a unique pharmacology compared to other mammalian bombesin receptors. J Biol Chem 1997;272:26062-71.
49. Moody TW, Mantey SA, Pradhan TK, Schumann M, Nakagawa T, Martinez A et al. Development of high affinity camptothecin-bombesin conjugates that have targeted cytotoxicity for bombesin receptor-containing tumor cells. J Biol Chem 2004;279:23580-9.
50. Rozengurt E, Sinett-Smith J. Bombesin stimulation of DNA synthesis and cell division in cultures of Swiss 3T3 cells. Proc Natl Acad Sci USA 1983;80:2936-40.
51. Zia F, Jacobs S, Kull F Jr, Cuttitta F, Mulshine J, Moody TW. Monoclonal antibody (IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem 1996;24s:269-75.
52. Lui VW, Thomas SM, Wentzel AM, Siegfried JM, Li JY, Grandis JR. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003;22:6183-93.
53. Zhang Q, Thomas SM, Smithgall TE, Siegfried JM, Kamens J, Gooding WE et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64:6166-73.
54. Doerdahl G, Betsholtz C, Johansson A, Nilsson K, Bergh J. Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small cell human lung carcinoma lines. Int J Cancer 1988;41:636-41.
55. Moody TW, Lee M, Kris RM, Bellot F, Bepler G, Oie H et al. Lung carcinoid cell lines have bombesin-like peptides and EGF receptors. J Cell Biochem 1990;43:139-47.
56. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-12.
57. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993;68:162-5.
58. Silvestri GA, Rivera MP. Targeted therapy for treatment of advanced non-small cell lung cancer. Chest 2005;128:3975-84.
59. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Couillard JY et al Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
60. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
61. Wood SM, Wood JR, Ghatei MA, LeeYC, O'Shaughnessy D, Bloom SR. Bombesin, somatostatin and neurotensin-like immunoreactivity in bronchial carcinoma. J Clin Endocrinol Metab 1981;53:1310-2.
62. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalamus. J Biol Chem 1973;248:6854-61.
63. Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci 1999;20:302-9.
64. Allen AE, Carney DN, Moody TW. Neurotensin binds with high affinity to small cell lung cancer cells. Peptides 1988;9s:57-61.
65. Bunn PA Jr, Dienhart DG, Chan D, Puck TT, Tagawa M, Jewett PB et al. Neuropeptide stimulation of calcium flux in human lung cancer cells. Proc Natl Acad Sci USA 1990;87:2162-6.
66. Davis TP, Burgess HS, Crowell S, Moody TW, Culling-Berglund A, Liu RH. β-Endorphin and neurotensin stimulate in vitro clonal growth of human SCLC cells. Eur J Pharmacol 1989;161:283-5.
67. Moody TW, Mayr CA, Gillespie T, Davis TP. Neurotensin is metabolized by endogenous proteases in prostate cancer cells. Peptides 1998;19:253-8.
68. Kitabgi P, Checkler J, Mazella J, Vincent JP. Pharmacology and biochemistry of neurotensin receptors. Rev Clin Basic Pharmacol 1985;5:397-486.
69. Bourdel E, Doulut S, Jarretou C, Labbe-Jullie JA, Fehrentz O, Coumbi P et al. New hydroxamate inhibitors of neurotensin-degrading enzymes: synthesis and enzyme active-site recognition. Int J Pept Protein Res 1996;48:148-55.
70. Rodriguez-Fernandez JL, Rozengurt E. Bombesin, vasopressin, lysophosphatidic acid and sphingosylphosphorylcholine induce focal adhesion kinase activation in intact Swiss 3T3 cells. J Biol Chem 1998;273:19321-8.
71. Frisch SM, Vuori K, Raoslahti E, Chan-Hui PY. Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cells. J Cell Biol 1996;134:793-8.
72. Akasaka T, van Leeuwen RI, Yoshinaga IL, Mihm MC Jr, Byers HR. Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines. J Invest Dermatol 1995;105:104-8.
73. Owens LV, Xu LH, Craven RJ, Dent GA, Weiner TM, Kornberg L et al. Overexpression of focal adhesion kinase (p125FAK) in invasive tumors. Cancer Res 1995;55:2752-5.
74. Wang D, Grammer JR, Cobbs CS, Stewart JE, Liu Z, Rhoden R et al. p125FAK promotes malignant astrocytoma cell proliferation in vivo. J Cell Sci 2000;113:4221-30.
75. Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192:553-60.
76. Kitamura K, Sakata J, Dangawa K, Kojima M, Matsuo H, Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 1993;194:720-5.
77. Buhlmann N, Leuthauser K, Muff R, Fischer JA, Born W. A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 1999;140:2883-90.
78. Garayoa M, Martinez A, Lee S, Pio R, An WG, Neckers L et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000;14:848-62.
79. Nakayama N, Takahashi K, Murakami O, Shirato K, Shibahara S. Induction of adrenomedullin by hypoxia and cobalt chloride in human colorectal carcinoma cells. Biochem Biophys Res Commun 1998;243:514-7.
80. Draoui M, Moody TW, Fathi Z, Battey J. GRP gene expression is stimulated in small cell lung cancer cells by phorbol ester. Cell Growth Diff 1993;4:723-9.
81. Martínez A, Vos M, Guédez L, Kaur G, Chen Z, Garayoa M et al. The effects of adrenomedullin in breast tumor cells. J Natl Cancer Inst 2002;94:1226-37.
82. Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells. A possible promotion mechanism for tumour growth. Oncogene 2001;20:2937-45.
83. Iimuro S, Shindo T, Moriyama N, Amaki T, Niu P, Takeda N et al Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 2004;95:415-23.
84. Casibang M, Purdom S, Zia F, Jakowlew S, Neckers L, Ben-Av P, Hla T et al. Prostaglandin E2 increases vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer 2001;31:203-12.
85. Martinez A, Zudaire E, Portal-Nunez S, Guedez L, Libutti SK, Stetler-Stevenson W et al. Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, its inhibition results in reduction of tumor growth. Cancer Res 2004;64:6489-94.
86. Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 2005;1755:37-69.
87. Zhang X, Green KE, Yallampalli C, Dong YL. Adrenomedullin enhances invasion by trophoblast cell lines. Biol Reprod 2005;73:619-26.
88. Martínez A, Oh HR, Unsworth EJ, Brenonzio C, Saavedra JM, Stetler-Stevenson WG et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasconstrictor out of a vasodilator. Biochem J 2004;383:413-8.
89. Pio R, Martinez A, Unsworth EJ, Kowalak JA, Bengoechea JA, Zipfel PF et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001;276:12292-300.
90. Ajona D, Castaño Z, Garayoa M, Zudaire E, Pajares MJ, Martínez A et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 2004;64:6310-8.
91. Katz Y, Gur S, Aladjem M, Strunk RC. Synthesis of complement protein in amnion. J Clin Endocrinol Metab 1995;80:2027-32.